Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 14/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 14/20 | 0.51 |
| ▸ | FSCN1 | Q16658 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL367959 | 0.87 | CYP17A1 (0.51) | CYP17A1CYP1A2FSCN1 | |
| SCHEMBL368499 | 0.85 | CYP17A1 (0.58) | CYP17A1CYP1A2 | |
| SCHEMBL368610 | 0.84 | CYP17A1 (0.57) | CYP17A1CYP1A2 | |
| SCHEMBL367421 | 0.80 | CYP17A1 (0.55) | CYP17A1CYP1A2 | |
| SCHEMBL15105996 | 0.68 | CYP17A1 (0.61) | CYP17A1CYP1A2 | |
| SCHEMBL368118 | 0.68 | CYP17A1 (1.00) | CYP17A1CYP1A2 | |
| SCHEMBL358823 | 0.66 | CYP17A1 (1.00) | CYP17A1CYP1A2 | |
| SCHEMBL368159 | 0.65 | CYP17A1 (0.68) | CYP17A1CYP1A2 | |
| SCHEMBL367760 | 0.65 | CYP17A1 (0.68) | CYP17A1CYP1A2 | |
| SCHEMBL368498 | 0.65 | CYP17A1 (0.67) | CYP17A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593453-B1 | AZAINDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-17 | — | — | EP | claimed |
| US-8673922-B2 | Azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-18 | — | — | US | claimed |
| US-20130184254-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2013-07-18 | — | — | US | claimed |
| EP-2593453-A1 | AZAINDAZOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2013-05-22 | — | — | EP | claimed |
| WO-2012009510-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-19 | — | — | WO | claimed |
| EP-2593453-B1 | AZAINDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-17 | — | — | EP | disclosed |
| US-8673922-B2 | Azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130184254-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2013-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184254-A1 | AZAINDAZOLE COMPOUNDS | CYP3A4, CYP4B1, CYP3A43 | CYP17A1 53/4885CYP1A2 9/4885FSCN1 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.